Chronic myeloid leukemia (CML) is the result of the constitutive kinase activity of the tyrosine kinase BCR-Abl, the product of the bcr-abl gene fusion present on the Philadelphia chromosomes of patients with CML [1]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.